ABSTRACT
ObjectiveTo characterize the efficacy components of Guizhi Jia Gegentang（GGT） in intervening influenza virus pneumonia by ultra-performance liquid chromatography-quadrupole-electrostatic field orbitrap high resolution mass spectrometry（UPLC-Q-Exactive Orbitrap MS）. MethodBALB/c mice were randomly divided into normal group and GGT group（36 g·kg-1·d-1） with six mice in each group. GGT group was continuously administered GGT extract for 5 d， while the normal group was administered an equal amount of ultrapure water. Serum and lung tissue were collected after administration， and UPLC-Q-Exactive Orbitrap MS was used to characterize the prototypical and metabolic components of GGT in serum and lung tissue of mice. The components existed simultaneously in the serum and lung tissue of mice from the GGT group were defined as its functional components， and the targets of efficacy components were searched by SwissTargetPrediction database， and GeneCards database was used to query the target of influenza virus pneumonia， and then the intersection was taken to obtain potential targets of GGT for intervening in the disease. Protein-protein interaction（PPI） network analysis of potential targets was performed by STRING database， and Kyoto Encyclopedia of Genes and Genomes（KEGG） pathway enrichment analysis on potential targets was performed by Metascape. ResultA total of 29 prototypical components and 28 metabolic components of GGT were detected in the drug-containing serum of mice， of which 11 prototypical components and 4 metabolic components were detected in the lung tissue of mice. The main metabolic pathways included reduction， hydroxylation， methylation， glucuronidation and sulfation. The results of PPI network and KEGG analysis showed that these functional components may act through their effects on targets such as albumin（ALB）， epidermal growth factor receptor（EGFR）， steroid receptor coactivator（SRC）， Toll-like receptor 4（TLR4）， nuclear transcription factor（NF）-κB and adhesion junction. ConclusionThe 11 prototypical components and 4 metabolites present simultaneously in the drug-containing serum and lung tissue of mice may be the potential therapeutic components of GGT in interfering with influenza viral pneumonia， and act through interfering with inflammatory metabolic pathways. This study can provide a reference for the mechanism study of GGT in the treatment of influenza viral pneumonia.
ABSTRACT
Objective:To explore the clinical characteristics, outcomes and influencing factors of influenza A virus-induced pneumonia in renal allograft recipients.Methods:During the 2015-2019 influenza season, 21 patients with influenza A virus-induced pneumonia after renal transplantation(RT)were prospectively recruited with 42 matched non-immunocompromised inpatients with influenza A virus-induced pneumonia.Clinical data, outcomes and follow-up observations after discharge were collected for analyzing the clinical characteristics of influenza A virus-induced pneumonia after RT.Continuous variables were compared by t-test or Mann-Whitney U test.And categorical variables were compared by Chi-Square test.Results:The median time after RT was 5(0.88, 10.50)years for RT recipients.In RT group, none received seasonal influenza vaccination with a vaccination rate of zero.The influenza vaccination rate of non-immunocompromised patients in current season was 42.86%(18/42)and inter-group difference was statistically significant( P<0.001). The levels of hemoglobin, aspartate aminotransferase, alanine aminotransferase and lactate dehydrogenase in RT recipients were(108.47±22.39)g/L, 21.00(16.00, 46.50)U/L, 15.00(12.00, 21.00)U/L and 314.00(207.25, 374.00)U/L.And the values were lower than those of non-immunocompromised patients[(130.24±21.74)g/L, 48.50(36.00, 79.50)U/L, 32.00(20.00, 52.25)U/L and 466.00(227.00, 781.75)U/L]. The differences were statistically significant( P=0.001, P<0.001, P<0.001, P=0.005). The levels of blood urea nitrogen and serum creatinine were 8.27(6.69, 12.48)mmol/L and 130.30(94.15, 204.70)mmol/L versus 5.42(3.37, 7.65)mmol/L and 65.90(48.98, 82.13)mmol/L in non-immunocompromised patients.The differences were statistically significant(all P< 0.001). No significant differences existed in the levels of C-reactive protein and procalcitonin between RT recipients and non-immunocompromised patients( P=0.774 and 0.821). The level of ESR and oxygenation index at admission were 39.00(13.00, 53.00)mm/h and(306.95±90.97)in renal recipients and 18.00(11.50, 23.00)mm/h and(200.17±116.35)in non-immunocompromised patients.The differences were statistically significant( P=0.045 and 0.001). Imaging studies indicated that multiple lobar involvement was a major imaging feature in both renal recipients and non-immunocompromised patients.The probability of pulmonary consolidation was 33.33%(7/21)in renal recipients and it was lower than that in non-immunocompromised patients.And the probability of pleural effusion was 42.86%(9/21)and it was higher than control.The inter-group differences were statistically significant( P=0.020 & 0.024). Rate of mechanical ventilation, CRRT and mortality were 42.86%(9/21), 23.81%(5/21)and 28.57%(6/21). All of them were higher than non-immunocompromised patients[21.43%(9/42), 9.52%(4/42)and 9.52%(4/42)]. However, there was no significant inter-group difference( P=0.076, 0.252 & 0.113). The median score of CURB-65 was 1(0.5, 1). Conclusions:Renal damage is prominent in hospitalized patients with influenza A virus-induced pneumonia after RT.There are a high rate of mechanical ventilation and CRRT during hospitalization and a high mortality.The prognosis remains poor for hospitalized patients with influenza A virus-induced pneumonia after RT.No matter how serious their conditions are at admission, they need to be closely monitored and aggressively treated.
ABSTRACT
Objective To analyze the clinical characteristics of community-acquired influenza virus pneumonia in hospitalized children and improve the clinicians' understanding level of this disease.Methods Data of 70 cases with community-acquired influenza virus pneumonia admitted to the Respiratory Department and Infectious Disease,Beijing Children's Hospital,Capital Medical University,from November 2009 to April 2018 were collected and the clinical characteristics were analyzed.Results Of the 70 cases,61 cases(89.7％) were discharged after improvement.The median age was 3.5 years old,and 50 cases(71.4％) were 0 to 5 years old.There were 29 cases with severe influenza pneumonia,41 cases with mild influenza pneumonia,3 cases died,and 19 cases (27.1％) had underlying diseases.Sixty-four cases (91.4％) were hospitalized in winter and spring.The first symptoms were mainly fever in 64 cases (91.4％) and cough in 65 cases (92.9％),and temperatures were mostly from 39.1 ℃ to 41.0 ℃.Lung auscultation was dominated by moist rales (30 cases,58.8％) and wheezing (8 cases,15.7％).There were many complications of influenza virus pneumonia,including 19 cases with myocardial injury,11 cases with liver function injury,4 cases with toxic encephalopathy,3 cases with electrolyte disturbance,2 cases with multiple organ failure,2 cases with hemophagocytic syndrome,and 1 case with septic shock.Chest radiographic results reveal bilateral inflammation in 40 children (57.1％),prodominatly in lower lobe lesions (39 cases).The common changes were patchy shadow,interstitial parenchymal lesion,ground glass shadow,and pleural effusion.Forty-seven children (67.1％) were infected by influenza A,and 23 children(32.9％) were co-infected.The percentage of severe cases with underlying diseases (68.4％) was significantly higher than that in children without chronic diseases (31.4％),the difference was statistically significant (x2 =7.830,P =0.005).The increase rate of C reaction protein (CRP) in severe cases (54.3％) was significantly higher than that in mild cases (28.6％),the difference was statistically significant (x2 =4.769,P =0.029).Conclusions Community-acquired influenza virus pneumonia in children mainly occurs in winter and spring.It is more common seen in children under 5 years of age.The main clinical manifestations of community-acquired influenza virus pneumonia are high fever and cough,extrapulmonary complications are more common.Most children have moist rales and showed bilateral inflammation and lower lobe lesions in chest radiography.Children with underlying diseases are more likely to develop severe influenza virus pneumonia.Elevated CRP is associated with severe influenza virus pneumonia.Most patients have a good prognosis,but there are still cases of death.
ABSTRACT
Objective To investigate the effect of Tanreqing injection assisted ganciclovir on children with respiratory syncytial virus pneumonia . Methods 145 cases of RSVP pediatric patientsin from February 2013 to January 2016 in our hospital were retrospectively chosen,according to different drug regimen,they were divided into two groups,the contronl group of 71 cases with ganciclovir injection treatment and study group of 74 cases,with Tanreqing injection treatment on the basis of the contronl group.The blood gas analysis was performed on the arterial blood of the two groups before treatment and 7 and 14 days after continuous administration.The changes of blood gas indexes (pH,PaO2,PaCO2) were compared.The lung rales, wheezing, fever, cough, wheeze disappearance of time and side effects of the children were recorded.Results After 7 and 14 days of treatment, the Ph of blood gas parameters in the study group were (7.38 ±0.21) and (7.41 ±0.26), the level of PaO2 were (96.45 ±4.06) mmHg and (98.84 ± 5.27) mmHg,which were significantly higher than those of the control group (P<0.05);the level of PaCO2 in the study group were(45.02 ±4.23) mmHg and (41.26 ±3.16) mmHg, which were significantly lower than those in the contronl group (P<0.05).The rale resorption time in the study group was (4.47 ±1.06) days, the duration of wheezing subsided was (5.03 ±0.43) days, the duration of wheezing was (4.89 ±0.72) days, the duration of fever subsided was (2.46 ±0.32) days, the duration of cough was (8.41 ±1.54) days,were significantly lower than the control group(P<0.05).The adverse reaction rate in the study group was 8.11%, significantly lower than that in the control group 21.13%(P<0.05).Conclusion The combination of Tanreqing injection combined with ganciclovir has a good effect on children with RSVP , and can significantly shorten the time of clinical evidences such as wheezing, wheezing and pulmonary rales, and improve the blood gas level in children,reduce adverse reactions.
ABSTRACT
Objective To evaluate the clinical efficacy of Tanreqing injection combined with ganciclovir in the treatment of pediatric respiratory syncytial virus pneumonia.Methods Ninety cases of children with respiratory tract virus pneumonia were selected in our hospital from August 2014 to December 2015,and were randomly divided into observation group and control group,and 45 cases in each group.The control group was given conventional anti infection,expectorant and antiasthmatic,antipyretic,atomization inhalation symptomatic and supportive treatment,on this basis the ganciclovir injection;the observation group was additionally given Tanreqing treatment on the basis of the control group.Then we compared the effects of two groups,pulmonary rales,wheezing,cough disappeared time,hospitalization time and the incidence of adverse reactions.Results After the treatment,the total efficiency of the observation group (93.3％) was significantly higher than that of control group (75.6％),the difference was statistically significant (P ＜ 0.05).The pulmonary rales (5.58 + 1.41),cough (5.78 + 1.61),wheezing (3.45 + 0.87) disappear time and hospital stay time (5.34 ± + 0.61) of patients in the observation group was significantly shorter than that of the control group (6.93 + 1.61,7.73 + 1.65,479 + 1.02,736,0.52),and the difference was statistically significant (P ＜ 0.05).The adverse reaction incidence in the observation group (20.0％) and the control group (22.2％) had no statistically significant difference (P ＞ 0.05) Conclusion Tanreqing injection combined with ganciclovir in the treatment of children with respiratory syncytial virus pneumonia has good efficacy and less adverse reactions,it is worthy of further research and application in clinic.
ABSTRACT
0.5,the variance 0.5,variance coefficient
ABSTRACT
For example of children virus pneumonia, we put forward that clinical research should be carried out by review article analysis, experts’opinions integrated and the requests of evidence-based medicine. On the base of systemic evaluation of the sensitivity, reliability, validity and relation among them of all indicators for effect evaluation on virus pneumonia, we will establish the effect evaluation system of TCM in the treatment of virus pneumonia including disease and syndrome effect evaluation, complication and combining drug,using rate evaluation, safety evaluation and health economics evaluation.
ABSTRACT
Varicella-zoster virus (VZV) is a member of the herpesviridae, which shares the characteristics of latent infection and reactivation. VZV causes two distinct clinical entities; varicella (chickenpox) and herpes zoster (shingles). Varicella pneumonia is the most common complication of adult varicella, especially in patients who are immunocompromised. We present two cases of VZV pneumonia occuring in patients with systemic lupus erythematosus (SLE) who were being treated with cytotoxic drugs and steroid. Both patients were treated with acyclovir and responses were good.
Subject(s)
Adult , Humans , Acyclovir , Chickenpox , Herpes Zoster , Herpesviridae , Herpesvirus 3, Human , Lupus Erythematosus, Systemic , PneumoniaABSTRACT
Varicella-zoster virus (VZV) is a member of the herpesviridae, which shares the characteristics of latent infection and reactivation. VZV causes two distinct clinical entities; varicella (chickenpox) and herpes zoster (shingles). Varicella pneumonia is the most common complication of adult varicella, especially in patients who are immunocompromised. We present two cases of VZV pneumonia occuring in patients with systemic lupus erythematosus (SLE) who were being treated with cytotoxic drugs and steroid. Both patients were treated with acyclovir and responses were good.
Subject(s)
Adult , Humans , Acyclovir , Chickenpox , Herpes Zoster , Herpesviridae , Herpesvirus 3, Human , Lupus Erythematosus, Systemic , PneumoniaABSTRACT
OBJECTIVE:To evaluate the economic effectiveness of different pharmacotherapeutic schemes for the same disease METHODS:Using retrospective study and pharmacoeconomical cost-effective analysis,five schemes for child virus pneumonia were compared RESULTS:There were no significant differences in efficacy among scheme A,B,C,D and E (X2=3 248,P=0 517) The costs of scheme A,B,C,D and E were 2 457 76,2 446 74,1 642 56,2 062 26 and 1 476 6 yuans and cost-effectiveness ratios obtained by sensitivity analysis were 26 08,30 58,17 67,26 16 and 19 61 respectively CONCLUSI_ON:Pharmacoeconomically,scheme C is the most effective,the safest and the most economical one among five schemes